BAKER BROS. ADVISORS LP Q4 2016 Filing
Filed February 14, 2017
Portfolio Value
$10.2B
Holdings
133
Report Date
Q4 2016
Filing Type
13F-HR
All Holdings (133 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | 45,711,856 | $2.4T | 23646.93% | |
| 2 | INCYIncyte Corporation | 23,499,087 | $2.4T | 23098.33% | |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | 6,543,295 | $800.6B | 7848.00% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 25,819,768 | $744.6B | 7299.72% | |
| 5 | —Incyte Corporation | 274,500,000 | $558.6B | 5476.44% | |
| 6 | —Incyte Corporation | 259,000,000 | $518.1B | 5079.31% | |
| 7 | —Genomic Health, Inc. | 13,770,302 | $404.7B | 3967.36% | |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 4,806,483 | $398.2B | 3903.25% | |
| 9 | —DBV Technologies S.A. | 5,509,560 | $193.6B | 1897.38% | |
| 10 | —Aquinox Pharmaceuticals, Inc. | 10,536,092 | $174.0B | 1705.24% | |
| 11 | ONCBeiGene, Ltd. | 3,673,175 | $111.5B | 1093.21% | |
| 12 | ABBVAbbVie Inc. | 1,685,994 | $105.6B | 1034.97% | |
| 13 | —BioMarin Pharmaceutical Inc. | 22,379,000 | $90.5B | 887.47% | |
| 14 | BCRXBioCryst Pharmaceuticals, Inc. | 10,963,944 | $69.4B | 680.35% | |
| 15 | AMRNAmarin Corporation plc | 22,169,509 | $68.3B | 669.37% | |
| 16 | —Bellicum Pharmaceuticals, Inc. | 4,865,647 | $66.3B | 649.64% | |
| 17 | —Spark Therapeutics, Inc. | 1,318,341 | $65.8B | 644.89% | |
| 18 | —Acorda Therapeutics, Inc. | 3,301,791 | $62.1B | 608.51% | |
| 19 | —Achaogen, Inc. | 4,582,382 | $59.7B | 584.88% | |
| 20 | —Advanced Accelerator Applications S.A. | 2,167,137 | $58.0B | 568.51% | |
| 21 | NVTA1EURInvitae Corporation | 7,288,300 | $57.9B | 567.29% | |
| 22 | CERSCerus Corporation | 13,053,275 | $56.8B | 556.63% | |
| 23 | EX9Exelixis, Inc. | 3,003,569 | $44.8B | 439.01% | |
| 24 | NBIXNeurocrine Biosciences, Inc. | 895,422 | $34.7B | 339.70% | |
| 25 | HRTXHeron Therapeutics, Inc. | 2,383,569 | $31.2B | 306.10% | |
| 26 | —Versartis, Inc. | 1,920,845 | $28.6B | 280.57% | |
| 27 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $27.4B | 268.41% | |
| 28 | —Progenics Pharmaceuticals, Inc. | 3,150,808 | $27.2B | 266.87% | |
| 29 | —Acorda Therapeutics, Inc. | 35,083,000 | $26.6B | 260.47% | |
| 30 | MRUSMerus N.V. | 1,160,014 | $24.5B | 240.06% | |
| 31 | XNCRXencor, Inc. | 872,072 | $23.0B | 225.01% | |
| 32 | ARRYEURArray BioPharma Inc. | 2,585,913 | $22.7B | 222.82% | |
| 33 | —bluebird bio, Inc. | 351,441 | $21.7B | 212.57% | |
| 34 | ASNDAscendis Pharma A/S | 1,023,266 | $20.7B | 203.03% | |
| 35 | —Derma Sciences, Inc. | 3,752,390 | $19.5B | 191.28% | |
| 36 | —Aegerion Pharmaceuticals, Inc. | 26,517,000 | $19.1B | 187.27% | |
| 37 | GLPGGalapagos NV | 259,894 | $16.7B | 163.54% | |
| 38 | —Idera Pharmaceuticals, Inc. | 10,272,314 | $15.4B | 151.04% | |
| 39 | —AveXis, Inc. | 315,300 | $15.0B | 147.53% | |
| 40 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $13.9B | 136.50% | |
| 41 | —Aimmune Therapeutics, Inc. | 673,908 | $13.8B | 135.10% | |
| 42 | HALOHalozyme Therapeutics, Inc. | 1,391,507 | $13.7B | 134.77% | |
| 43 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.7B | 134.62% | |
| 44 | —NeuroDerm Ltd. | 571,667 | $12.7B | 124.41% | |
| 45 | GBYSangamo Therapeutics, Inc. | 4,055,876 | $12.4B | 121.26% | |
| 46 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $11.3B | 111.08% | |
| 47 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $10.8B | 105.67% | |
| 48 | SG7Sage Therapeutics, Inc. | 208,328 | $10.6B | 104.27% | |
| 49 | —Zogenix, Inc. | 838,809 | $10.2B | 99.91% | |
| 50 | —Dermira, Inc. | 326,428 | $9.9B | 97.06% | |
| 51 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $9.2B | 90.11% | |
| 52 | ALKSAlkermes plc | 150,251 | $8.4B | 81.86% | |
| 53 | —Abeona Therapeutics Inc. | 1,684,364 | $8.2B | 80.08% | |
| 54 | —Achillion Pharmaceuticals, Inc. | 1,856,637 | $7.7B | 75.17% | |
| 55 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $7.5B | 73.10% | |
| 56 | MGNXMacroGenics, Inc. | 363,676 | $7.4B | 72.88% | |
| 57 | —ContraFect Corporation | 4,045,876 | $7.1B | 69.41% | |
| 58 | IMGNEURImmunoGen, Inc. | 3,015,353 | $6.2B | 60.30% | |
| 59 | —Dimension Therapeutics, Inc. | 1,251,881 | $5.4B | 53.39% | |
| 60 | AGIOAgios Pharmaceuticals, Inc. | 128,666 | $5.4B | 52.63% | |
| 61 | CPRXCatalyst Pharmaceuticals, Inc. | 5,102,153 | $5.4B | 52.51% | |
| 62 | IM8NInsmed Incorporated | 400,000 | $5.3B | 51.88% | |
| 63 | —Inotek Pharmaceuticals Corporation | 5,000,000 | $5.2B | 50.65% | |
| 64 | —Alcobra Ltd. | 2,336,359 | $4.9B | 48.09% | |
| 65 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,018,882 | $4.8B | 47.10% | |
| 66 | BIIBBiogen Inc. | 16,500 | $4.7B | 45.87% | |
| 67 | —Aevi Genomic Medicine, Inc. | 880,539 | $4.6B | 44.71% | |
| 68 | —Alder BioPharmaceuticals, Inc. | 217,328 | $4.5B | 44.31% | |
| 69 | —Loxo Oncology, Inc. | 137,735 | $4.4B | 43.36% | |
| 70 | —Array BioPharma Inc. | 3,000,000 | $4.2B | 41.12% | |
| 71 | —Stemline Therapeutics, Inc. | 333,497 | $3.6B | 34.98% | |
| 72 | RAREUltragenyx Pharmaceutical Inc. | 50,000 | $3.5B | 34.47% | |
| 73 | —Akari Therapeutics plc | 496,901 | $3.5B | 34.29% | |
| 74 | NERVGBPMinerva Neurosciences, Inc. | 258,805 | $3.0B | 29.81% | |
| 75 | ASMBAssembly Biosciences, Inc. | 250,000 | $3.0B | 29.78% | |
| 76 | —Ignyta, Inc. | 571,000 | $3.0B | 29.66% | |
| 77 | SELBUSDSelecta Biosciences, Inc. | 175,712 | $3.0B | 29.54% | |
| 78 | NTRANatera, Inc. | 249,269 | $2.9B | 28.61% | |
| 79 | —Adamas Pharmaceuticals, Inc. | 172,630 | $2.9B | 28.60% | |
| 80 | —Epizyme, Inc. | 232,481 | $2.8B | 27.58% | |
| 81 | ISIIonis Pharmaceuticals, Inc. | 57,140 | $2.7B | 26.79% | |
| 82 | —Ra Pharmaceuticals, Inc. | 177,952 | $2.7B | 26.50% | |
| 83 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $2.7B | 26.32% | |
| 84 | —Trevena, Inc. | 450,000 | $2.6B | 25.94% | |
| 85 | ENTAEnanta Pharmaceuticals, Inc. | 75,357 | $2.5B | 24.74% | |
| 86 | —Syros Pharmaceuticals, Inc. | 204,465 | $2.5B | 24.37% | |
| 87 | —Osiris Therapeutics, Inc. | 499,193 | $2.5B | 24.03% | |
| 88 | TREURTrillium Therapeutics Inc. | 413,697 | $2.3B | 22.91% | |
| 89 | GLYCEURGlycoMimetics, Inc. | 381,235 | $2.3B | 22.80% | |
| 90 | —Protalix BioTherapeutics, Inc. | 3,423,000 | $2.3B | 22.48% | |
| 91 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 260,129 | $2.2B | 21.55% | |
| 92 | —Nabriva Therapeutics AG | 350,000 | $2.1B | 20.45% | |
| 93 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.0B | 20.00% | |
| 94 | AGLEUSDAeglea BioTherapeutics, Inc. | 404,230 | $1.8B | 17.23% | |
| 95 | —Spring Bank Pharmaceuticals, Inc. | 219,298 | $1.8B | 17.17% | |
| 96 | —InVivo Therapeutics Holdings Corp. | 400,000 | $1.7B | 16.47% | |
| 97 | CNCEEURConcert Pharmaceuticals, Inc. | 152,964 | $1.6B | 15.43% | |
| 98 | —Juno Therapeutics, Inc. | 80,000 | $1.5B | 14.78% | |
| 99 | SCYXEURSCYNEXIS, Inc. | 467,600 | $1.5B | 14.63% | |
| 100 | FLGTFulgent Genetics, Inc. | 125,000 | $1.4B | 14.18% |
Page 1 of 2Next